Paid

Over $20 Million Carved Out From Statistical, Operations enters 2

NCI: NCTN Makes “Amazing Trials” Possible“It is important to note that the $151 million does not capture the many other functions that NCI provides in support of the NCTN and the entire clinical trials enterprise,” Garrett said. “A few of these key centralized functions include the Cancer Trials Support Unit (CTSU), a 'one-stop shop' for the groups to access all trials, a Central Institutional Review Board (CIRB) to eliminate the need for local IRB approvals, tumor banking for each group, and ancillary studies funded to support biomarker and quality of life research.
Drugs & Targets

ADXS-HPV grated orphan drug designation

FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer. ADXS-HPV is an immunotherapy drug candidate, developed by Advaxis Inc., which is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into... […]